help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blackshear, P. J.
Right arrow Articles by Cohen, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blackshear, P. J.
Right arrow Articles by Cohen, A. M.

Journal of Clinical Endocrinology & Metabolism, Vol 61, 753-760, Copyright © 1985 by Endocrine Society

ARTICLES

Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients

PJ Blackshear, GI Shulman, AM Roussell, DM Nathan, KL Minaker, JW Rowe, DC Robbins and AM Cohen

We studied two obese type II diabetic patients before, during, and after 3 yr of continuous iv insulin infusion, delivered by means of totally implanted insulin infusion pumps. Tolerance of the devices was excellent, and no side-effects or episodes of significant hypoglycemia occurred. Glycosuria was eliminated, and mean 24-h plasma glucose and hemoglobin A1c levels decreased in both patients and remained in or near the normal range for 3 yr. Improvements were also noted in serum triglyceride concentrations and vitreous fluorescein concentrations after iv fluorescein injection. Euglycemic insulin clamp studies showed that no significant change in glucose disposal rate occurred after 6 and 12 months of treatment. However, some improvement in insulin secretion during hyperglycemic insulin clamp studies occurred in both patients after 6 months of insulin infusion. Evaluation of the insulin- glycerol mixture used in the pump revealed that moderate degradation of insulin occurred in the pump during the 21-day flow cycle, resulting in 6-12% increases in fasting blood glucose levels; in addition, higher mol wt species of immunoreactive insulin were present in the patients' serum. We conclude that long term continuous iv infusion of insulin using a totally implantable infusion pump is practical in type II diabetic patients, is acceptable to patients, and is capable of providing near-normal glycemic control.


This article has been cited by other articles:


Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Exploring Treatment Strategies for Type 2 Diabetes
Diabetes Care, October 1, 2007; 30(10): 2737 - 2745.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. M. Cohen
Society of Surgical Oncology Presidential Address: Friendships, Partnerships, and Teams--Keys to Academic Success
Ann. Surg. Oncol., September 1, 2004; 11(9): 798 - 806.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
C. D. Saudek
Implantable Insulin Infusion Pumps: A Case Presentation
The Diabetes Educator, January 1, 1989; 15(1): 44 - 49.
[PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society